Syneron Medical Ltd. (NSDQ:ELOS) reported a 250 percent increase in sales during 2010, as the aesthetic device maker began to see some payoff from its 2009 acquisition of Candela Corp.
Syneron, a Yokneam, Israel aesthetic device company reported $189 million in sales during the year ending on Dec. 31, 2010, compared to $54 million for the same period last year. Much of that increase is directly attributed to products the company picked up in its $65 million acquisition of Candela Corp. in Sept. 2009.
The boost in revenues did not help the company in its bottom line, however, as the company reported a net loss of $25 million, compared to a loss of $23.6 million in 2009.
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Neurologix annual losses ease
Neurologix Inc. (OTC:NRGX) reported losses of $10.2 million, or 48 cents per diluted share, on no revenues during the year ended Dec. 31, 2010. That compares with losses of $13.5 million, or 59 cents per diluted share, on no revenues in 2009.
Read more
Cellseed losses widen
Cellseed Inc. (JASDAQ:7776) reported losses of ¥1.01 billion ($12.4 million) on sales of ¥66 million ($807,000) during the year ended December 2010. That compares with losses of ¥790 million ($9.66 million) on sales of ¥87 million ($1.1 million) in 2009. (Conversion based on ¥1 = $0.0122)
Read more
Tearlab losses widen despite increased sales
Tearlab Corp. (NSDQ:TEAR) reported losses of $907,000, or 6 cents per diluted share, on sales of $798,000 during the three months ended Dec. 31. That compares with losses of $1.7 million, or 17 cents per diluted share, on sales of $265,000 during the same period in 2009.
Full-year losses were $6.7 million, or 47 cents per share, on sales of $1.7 million. That compares with losses of $4.4 million, or 44 cents per share, on sales of $869,000 in 2009.
Read more
MiMedx sinks deeper into the red
MiMedx Group Inc. (OTC:MDXG) reported losses of $11.4 million, or 19 cents per diluted share, on sales of $788,874 during the year ended Dec. 31, 2010. That compares with losses of $8.3 million, or 20 cents per diluted share, on sales of $800,000 during the nine months ended Dec. 31, 2009.
Read more
Sanuwave losses more than double
Sanuwave Health Inc. (OTC:SNWV) reported losses of $14.9 million, or $1.15 per diluted share, on sales of $728,446 during the year ended Dec. 31, 2010. That compares with losses of $6.2 million, or 54 cents per diluted share, on sales of $660,725 in 2009.
Read more
IVAX sales fall
IVAX Diagnostics Inc. (OTC:IVD) reported losses of $769,203, or 3 cents per diluted share, on sales of $4.0 million during the three months ended Dec. 31, 2010. That compares with losses of $1.3 million, or 5 cents per diluted share, on sales of $4.6 million during the same period in 2009.
Full-year losses were $4.2 million, or 15 cents per share, on sales of $17.0 million. That compares with losses of $4.5 million, or 16 cents per share, on sales of $18.4 million in 2009.
Read more
